Skip to content

Oocyte Zygote Embryo Maturation Arrest 17 C5830418

Published: July 22, 2026Updated: August 25, 2026

This genetic disorder prevents early embryo development from progressing normally, causing infertility and repeated failed pregnancies.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 25, 2026Editorial policy

Key facts at a glance

ICD-10
Q55.9
ICD-11
LA00.0
Body system
reproductive
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Generalized symptoms

(reproductive)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Infertility

(reproductive)

Delayed embryo cleavage

(reproductive)

Absent ovulation

(reproductive)

Decreased ovarian reserve

(reproductive)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Drug therapy with clinical monitoring

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Rescue ICSI with timed fertilization

Immediate ICSI performed on any mature oocytes retrieved, with close monitoring of fertilization and early embryonic development through cleavage stages.

procedure
3

Preimplantation genetic testing

Biopsy of embryos at blastocyst stage for genetic screening to identify euploid embryos suitable for transfer, particularly relevant given genetic basis of condition.

procedure

Additional treatment options

Mitochondrial support therapy

Pharmacological approaches including Coenzyme Q10 and other mitochondrial-targeted supplements to potentially improve oocyte energy metabolism and maturation.

medication

Decision-making support counseling

Specialized counseling to help patients navigate complex decisions regarding treatment options, including use of donor gametes and family-building alternatives.

psychological

Comprehensive fertility assessment

Serial ultrasounds and hormone monitoring throughout stimulation cycle to assess oocyte and embryo development, allowing for protocol adjustments.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Oocyte Zygote Embryo Maturation Arrest 17 C5830418?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Oocyte Zygote Embryo Maturation Arrest 17 C5830418. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy